November 20th 2020
As an introduction to a panel discussion on best practices using newer, novel therapies to treat plaque psoriasis, dermatology experts review what is now understood regarding the condition’s pathophysiology.
April W. Armstrong, MD, MPH, of the University of Southern California, comments on the clinical manifestation of plaque psoriasis on children and adult patients, and highlights comorbidities typically associated with the condition.
An overview of current treatments used as initial therapy to treat plaque psoriasis and factors that affect treatment selection.
A historical overview regarding the advances in biologic therapies to treat plaque psoriasis and real-world experience using newer classes of biologics in clinical practice.
Dermatology experts comment on the safety profiles of biologic therapies used to treat plaque psoriasis, highlight specific contraindications to be mindful of when prescribing these drugs, and provide suggestions to help mitigate the risk of adverse events.
Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center, highlights a newer class of biologics used to treat plaque psoriasis, IL-23 inhibitors, and explains how they differ from other classes of therapy.
Variables that dermatologists should consider when selecting an appropriate biologic therapy to treat a patient with plaque psoriasis, and the importance of shared decision-making.
Recommendations for treating plaque psoriasis with newer biologic therapies and factors that warrant a switch in therapy, either using another biologic of the same class or moving to a different class.
During a brief discussion on current treatment challenges in plaque psoriasis, key opinion leaders in dermatology highlight patient access and affordability of newer biologic therapies as the biggest hurdles faced by clinicians.
An overview of the most anticipated developments to come in plaque psoriasis treatment.
